Transplanting HCV-Infected Kidneys Into HCV-Infected Patients Increased Adjusted Life Expectancy

Share this content:
Unless the additional wait time for an uninfected kidney was less than 161 days, transplant of an HCV-uninfected kidney preceded by HCV treatment was not preferred.
Unless the additional wait time for an uninfected kidney was less than 161 days, transplant of an HCV-uninfected kidney preceded by HCV treatment was not preferred.

HealthDay News — For patients with hepatitis C virus (HCV) infection with end-stage renal disease, transplant of an HCV-infected kidney followed by treatment is more cost-effective than transplant of an HCV-uninfected kidney, according to a study published online July 10 in the Annals of Internal Medicine.

Mark H. Eckman, M.D., from the University of Cincinnati, and colleagues compared the cost-effectiveness of transplanting HCV-infected or HCV-uninfected kidneys into HCV-infected patients. Transplant of an HCV-infected kidney was followed by HCV treatment, while transplant of an uninfected kidney was preceded by treatment.

The researchers found that, compared with transplant of an uninfected kidney, preceded by treatment, transplant of an HCV-infected kidney, followed by HCV treatment, was more effective and less costly in base-case analysis; this was mainly due to longer wait times for uninfected kidneys. An average of 0.5 quality-adjusted life-years would be gained at a lifetime cost savings of $41,591 for a typical 57.8-year-old patient receiving hemodialysis. In sensitivity analysis, transplant of an HCV-infected kidney continued to be preferred. Unless the additional wait time for an uninfected kidney was less than 161 days, transplant of an HCV-uninfected kidney preceded by HCV treatment was not preferred.

"Transplanting HCV-infected kidneys into HCV-infected patients increased quality-adjusted life expectancy and reduced costs compared with transplanting HCV-uninfected kidneys into HCV-infected patients," the authors write.

The study was funded by a grant from Merck Sharp & Dohme.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters